Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LAP3 | P28838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12532788 | 1.00 | LTA4H (0.67) | LTA4HSLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2750285 | 1.00 | LTA4H (0.67) | LTA4HSLC6A2TAAR1MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL9021063 | 0.98 | MAOB (0.67) | LTA4HSLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL9021092 | 0.95 | LTA4H (0.61) | LTA4HSLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2736160 | 0.86 | LTA4H (0.61) | LTA4HSLC6A2MAOASIGMAR1SLC6A3 | |
| SCHEMBL9626485 | 0.85 | SLC6A2 (0.70) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL2747423 | 0.85 | TAAR1 (0.65) | SLC6A2TAAR1MAOASLC6A4SIGMAR1 | |
| SCHEMBL2747426 | 0.85 | TAAR1 (0.65) | SLC6A2TAAR1MAOASLC6A4SIGMAR1 | |
| SCHEMBL21583868 | 0.85 | TAAR1 (0.65) | SLC6A2TAAR1MAOASLC6A4SIGMAR1 | |
| SCHEMBL30211131 | 0.85 | TAAR1 (0.65) | SLC6A2TAAR1MAOASLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | ENTRADA THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
| EP-2212276-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068177-A1 | DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| WO-2007022241-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20030171435-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | DRUG ABUSE SCIENCES, INC. | 2003-09-11 | — | — | US | disclosed |
| EP-1331219-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | Drug Abuse Sciences, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1177175-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068198-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-16 | — | — | WO | disclosed |
| US-4329367-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | LTA4H 4157/4885SLC6A2 3436/4885TAAR1 4174/4885 |
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | HNRNPAB, SNRPE, HNRNPA2B1 | LTA4H 4097/4885SLC6A2 1820/4885TAAR1 4376/4885 |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | LTA4H 958/4885SLC6A2 173/4885TAAR1 76/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885SLC6A2 4575/4885TAAR1 3408/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | LTA4H 3095/4885SLC6A2 3898/4885TAAR1 3730/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | LTA4H 4147/4885SLC6A2 3422/4885TAAR1 4189/4885 |
| US-20030171435-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | TAAR5, CHAT, CES2 | LTA4H 2232/4885SLC6A2 5/4885TAAR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.